Novo Nordisk's Victoza receives first approval –in the EU
This article was originally published in Scrip
Novo Nordisk's GLP-1 analogue Victoza (liraglutide) has received marketing authorisation in the EU – its first approval – for the treatment of type 2 diabetes. The approval follows a CHMP positive opinion of Victoza in April (scripnews.com, April 24th, 2009).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.